Episodes
-
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
Not summarized yet
-
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
Not summarized yet
-
From "Say More": What Happens When AI Decides Your Medical Coverage
Not summarized yet
-
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
Not summarized yet
-
318: Drug pricing drops & psychedelics under fire
Not summarized yet
-
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
Not summarized yet
-
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
Not summarized yet
-
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
Not summarized yet
-
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Not summarized yet
-
313: Biotech layoffs, founder-focused VC, & a big pharma exit
Not summarized yet
-
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Not summarized yet
-
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
Not summarized yet
-
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
Not summarized yet
-
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
Not summarized yet
-
308: An ASCO preview & another Duchenne trial failure
Not summarized yet
-
307: More tumult at BIO & coercive care for sickle cell patients
Not summarized yet
-
306: Live! From the STAT Breakthrough Summit West
Not summarized yet
-
305: Everything you need to know about H5N1 bird flu
Not summarized yet
-
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
Not summarized yet
-
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account